Onsite at ESMO 2025, pharmaphorum spoke with Adrian Jubb, head of oncology and neurology clinical development at Corcept, and ...

Ipsen has reached an agreement to buy fellow French firm ImCheck Therapeutics in a deal that could be worth up to €1 billion ...

Takeda has partnered with China's Innovent Biologics for a pair of late-stage cancer therapies, in a deal that includes an ...

An oversubscribed seed funding round will give Procyon the financial resources it needs to launch its first diagnostic – ...

The company ended the first half of this year with €3.1 billion ($3.6 billion) in cash reserves, and is due to report its ...

Novo Nordisk's chairman Helge Lund and several other independent board members have indicated they will step down next month, ...

How overwhelming schedules and demanding clinical environments – as well as an increasingly overwhelming amount of ...